These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 31887831)

  • 1. [China cholesterol education program (CCEP) expert advice for the management of dyslipidaemias to reduce cardiovascular risk (2019)].
    ; ; ;
    Zhonghua Nei Ke Za Zhi; 2020 Jan; 59(1):18-22. PubMed ID: 31887831
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Status of cholesterol goal attainment for the primary and secondary prevention of atherosclerotic cardiovascular disease in dyslipidemia patients receiving lipid-lowering therapy: DYSIS-China subgroup analysis].
    Li Y; Zhao SP; Ye P; Yan XW; Mu YM; Wei YD; Hu DY;
    Zhonghua Xin Xue Guan Bing Za Zhi; 2016 Aug; 44(8):665-70. PubMed ID: 27545124
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [The new 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk: comparison with the ESC/EAS recommendations for the management of dyslipidemias].
    Catapano AL; Averna M; Faggiano P; Novo S
    G Ital Cardiol (Rome); 2014 Jan; 15(1):19-20. PubMed ID: 24503730
    [No Abstract]   [Full Text] [Related]  

  • 4. [Spanish interdisciplinary committee for cardiovascular disease prevention and the spanish society of cardiology position statement on dyslipidemia management. Differences between the European and american guidelines].
    Lobos Bejarano JM; Galve E; Royo-Bordonada MÁ; Alegría Ezquerra E; Armario P; Brotons Cuixart C; Camafort Babkowski M; Cordero Fort A; Maiques Galán A; Mantilla Morató T; Pérez Pérez A; Pedro-Botet J; Villar Álvarez F; González-Juanatey JR;
    Semergen; 2015 Apr; 41(3):149-57. PubMed ID: 25450438
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [China expert consensus on the management of dyslipidemia in postmenopausal patients with early-stage breast cancer].
    China Expert Group of Multidisciplinary Management of Dyslipidemia in Breast Cancer Patients with Endocrine Therapy
    Zhonghua Zhong Liu Za Zhi; 2017 Jan; 39(1):72-77. PubMed ID: 28104038
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [A perspective to lipid lowering therapy after ESC/EAS guidelines for the management of dyslipidaemias and the European guidelines on cardiovascular disease prevention in clinical practice].
    Ural D
    Turk Kardiyol Dern Ars; 2012 Jun; 40(4):293-7. PubMed ID: 22951844
    [No Abstract]   [Full Text] [Related]  

  • 7. Prevalence and treatment of atherogenic dyslipidemia in the primary prevention of cardiovascular disease in Europe: EURIKA, a cross-sectional observational study.
    Halcox JP; Banegas JR; Roy C; Dallongeville J; De Backer G; Guallar E; Perk J; Hajage D; Henriksson KM; Borghi C
    BMC Cardiovasc Disord; 2017 Jun; 17(1):160. PubMed ID: 28623902
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The utility of non-HDL in managing dyslipidemia of stage 5 chronic kidney disease.
    Pennell P; Leclercq B; Delahunty MI; Walters BA
    Clin Nephrol; 2006 Nov; 66(5):336-47. PubMed ID: 17140163
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cholesterol Guidelines: More Similar Than Different.
    Pokharel Y; Akeroyd JM; Virani SS
    Prog Cardiovasc Dis; 2016; 59(2):190-199. PubMed ID: 27497507
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Implications of American College of Cardiology/American Heart Association (ACC/AHA) Cholesterol Guidelines on Statin Underutilization for Prevention of Cardiovascular Disease in Diabetes Mellitus Among Several US Networks of Community Health Centers.
    Akhabue E; Rittner SS; Carroll JE; Crawford PM; Dant L; Laws R; Leo MC; Puro J; Persell SD
    J Am Heart Assoc; 2017 Jul; 6(7):. PubMed ID: 28673901
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Dyslipidemia management for secondary prevention in cardiovascular disease: from guidelines to clinical practice].
    Mattesini A; Masiero G; Barbieri L; Vizzari G; Tarantino F; La Manna A; Mauro C; Limbruno U; Rigattieri S; Castiglioni B; Marchese A; Musumeci G; Tarantini G
    G Ital Cardiol (Rome); 2019 Sep; 20(9 Suppl 1):44S-49S. PubMed ID: 31593190
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Diabetic Dyslipidemia Review: An Update on Current Concepts and Management Guidelines of Diabetic Dyslipidemia.
    Dake AW; Sora ND
    Am J Med Sci; 2016 Apr; 351(4):361-5. PubMed ID: 27079341
    [TBL] [Abstract][Full Text] [Related]  

  • 13. What's next for dyslipidemia management? The 2013 ACC/AHA Guidelines, the NLA recommendations, and beyond.
    Waite LH; Phan YL; Spinler SA
    J Am Pharm Assoc (2003); 2016; 56(3):284-92. PubMed ID: 27156942
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lipid-lowering therapy and lipid goal attainment in patients with metabolic syndrome in China: subgroup analysis of the Dyslipidemia International Study-China (DYSIS-China).
    Wang F; Ye P; Hu D; Min Y; Zhao S; Wang Y; Mu Y; Yan X; Li Z; Wei Y; Li J;
    Atherosclerosis; 2014 Nov; 237(1):99-105. PubMed ID: 25238215
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [2016 European Society of Cardiology guidelines for the management of dyslipidemias].
    Ferrières J
    Presse Med; 2017; 46(7-8 Pt 1):688-696. PubMed ID: 28502376
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Management of mixed dyslipidemia in patients with or at risk for cardiovascular disease: a role for combination fibrate therapy.
    Fazio S
    Clin Ther; 2008 Feb; 30(2):294-306. PubMed ID: 18343268
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prevalence of dyslipidemia and associated factors among the hypertensive population from rural Northeast China.
    Yu S; Yang H; Guo X; Zhang X; Zheng L; Sun Y
    BMC Public Health; 2015 Nov; 15():1152. PubMed ID: 26589291
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Management of Dyslipidemia in Individuals with Low-to-Moderate Cardiovascular Risk: Role of Nutraceuticals.
    Dolzhenko MM; Barnett OY; Grassos C; Dragomiretska NV; Goloborodko BI; Ilashchuk TO; Zuiev KO; Karpenko OV; Kolesnikova OV; Kolesnyk TV; Talaieva TV; Vakaliuk IP; Tiabut TD; Mesnikova IL; Zinych OV
    Adv Ther; 2020 Nov; 37(11):4549-4567. PubMed ID: 32979190
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Spanish Interdisciplinary Committee for Cardiovascular Disease Prevention and the Spanish Society of Cardiology position statement on dyslipidemia management. Differences between the European and American guidelines].
    Lobos Bejarano JM; Galve E; Royo-Bordonada MÁ; Alegría Ezquerra E; Armario P; Brotons Cuixart C; Camafort Babkowski M; Cordero Fort A; Maiques Galán A; Mantilla Morató T; Pérez Pérez A; Pedro-Botet J; Villar Álvarez F; González-Juanatey JR;
    Clin Investig Arterioscler; 2015; 27(1):36-44. PubMed ID: 25444651
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Differences in goal attainment in clinical management of dyslipidemia in China evaluated by different guidelines].
    Liang LR; Wu YF; Zhao LC; Chen Z; Zhu JR
    Zhonghua Xin Xue Guan Bing Za Zhi; 2009 Apr; 37(4):363-8. PubMed ID: 19791475
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.